Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Capitalistaon Aug 13, 2022 9:23pm
236 Views
Post# 34894642

RE:RE:RE:RE:RE:RE:Get ready for more merger mania in the pharma sector

RE:RE:RE:RE:RE:RE:Get ready for more merger mania in the pharma sector If a buyout is contemplated, existing share price means nothing.  If ONC's board votes to bring a BP offer to shareholders, the sale price per share will be the BP purchase price divided by the outstanding shares (plus exercised options and warrants).  There would be no need to find a mechanism to ramp up the existing market share price. 

The above is a "friendly takeover" scenario.  If it is a hostile takeover (the ONC BOD chooses not to recommend that shareholders tender their shares to the prospective buyer) then the buyer would have to find a price that's attractive to enough existing shareholders that they can accumulate enough shares to get effective control of the company.  We all have our trigger price . . . 
<< Previous
Bullboard Posts
Next >>